Last reviewed · How we verify

Propofol / Remifentanil — Competitive Intelligence Brief

Propofol / Remifentanil (Propofol / Remifentanil) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sedative-hypnotic (propofol) and opioid analgesic (remifentanil). Area: Anesthesia.

marketed Sedative-hypnotic (propofol) and opioid analgesic (remifentanil) GABA-A receptor (propofol); mu-opioid receptor (remifentanil) Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Propofol / Remifentanil (Propofol / Remifentanil) — University General Hospital of Patras. Propofol is a GABA-A receptor agonist that induces sedation/anesthesia, while remifentanil is a mu-opioid receptor agonist that provides analgesia and enhances sedation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Propofol / Remifentanil TARGET Propofol / Remifentanil University General Hospital of Patras marketed Sedative-hypnotic (propofol) and opioid analgesic (remifentanil) GABA-A receptor (propofol); mu-opioid receptor (remifentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sedative-hypnotic (propofol) and opioid analgesic (remifentanil) class)

  1. University General Hospital of Patras · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Propofol / Remifentanil — Competitive Intelligence Brief. https://druglandscape.com/ci/propofol-remifentanil. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: